{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:08:01Z","timestamp":1774984081648,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"DOI":"10.7759\/cureus.106218","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:42:02Z","timestamp":1774982522000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment-Emergent Bictegravir Resistance in a Treatment-Naive Individual With HIV Infection: A Case Report"],"prefix":"10.7759","author":[{"given":"Iya","family":"Dubson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aahana","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmin","family":"Jose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy I","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global HIV statistics \u2014 fact sheet. (2025). Accessed. February 20, 2026: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref2","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. (2025). Accessed. January 4, 2026: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescen...."},{"key":"ref3","unstructured":"HIV drug resistance - brief report 2024. (2024). Accessed. February 20, 2026: https:\/\/www.who.int\/publications\/i\/item\/9789240086319."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang M","year":"2016","unstructured":"Tsiang M, Jones GS, Goldsmith J, et al.. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016, 60:7086-97. 10.1128\/AAC.01474-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60616-x","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax PE","year":"2015","unstructured":"Sax PE, Wohl D, Yin MT, et al.. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015, 385:2606-15. 10.1016\/s0140-6736(15)60616-x","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US- 380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant J","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, et al.. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US- 380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017, 390:2063-72. 10.1016\/s0140-6736(17)32299-7","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax PE","year":"2021","unstructured":"Sax PE, Rockstroh JK, Luetkemeyer AF, et al.. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis. 2021, 73:e485-93. 10.1093\/cid\/ciaa988","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett K","year":"2017","unstructured":"Anstett K, Brenner B, Mesplede T, Wainberg MA. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017, 14:36. 10.1186\/s12977-017-0360-7","journal-title":"Retrovirology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000199","article-title":"Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors","volume":"28","author":"Oliveira M","year":"2014","unstructured":"Oliveira M, Mespl\u00e8de T, Quashie PK, Mo\u00efsi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS. 2014, 28:813-9. 10.1097\/QAD.0000000000000199","journal-title":"AIDS"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05181-14","article-title":"Combination of the R263K and M184I\/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity","volume":"59","author":"Singhroy DN","year":"2015","unstructured":"Singhroy DN, Wainberg MA, Mespl\u00e8de T. Combination of the R263K and M184I\/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrob Agents Chemother. 2015, 59:2882-5. 10.1128\/AAC.05181-14","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie PK","year":"2012","unstructured":"Quashie PK, Mespl\u00e8de T, Han YS, et al.. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012, 86:2696-705. 10.1128\/JVI.06591-11","journal-title":"J Virol"},{"key":"ref12","article-title":"2025 update of the drug resistance mutations in HIV-1","volume":"33","author":"Wensing AM","year":"2025","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F, et al.. 2025 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2025, 33:457-73.","journal-title":"Top Antivir Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29899","article-title":"High efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence","volume":"96","author":"Andreatta K","year":"2024","unstructured":"Andreatta K, D'Antoni ML, Chang S, et al.. High efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence. J Med Virol. 2024, 96:e29899. 10.1002\/jmv.29899","journal-title":"J Med Virol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104717","article-title":"Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient","volume":"179","author":"Lozano AB","year":"2020","unstructured":"Lozano AB, Chueca N, de Salazar A, et al.. Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient. Antiviral Res. 2020, 179:104717. 10.1016\/j.antiviral.2020.104717","journal-title":"Antiviral Res"},{"key":"ref15","article-title":"Development of integrase inhibitor resistance under first-line treatment with bictegravir","volume":"23 Suppl 7","author":"Stoll M","year":"2020","unstructured":"Stoll M, Braun P, Wiesmann F, Knechten H. Development of integrase inhibitor resistance under first-line treatment with bictegravir. J Int AIDS Soc. 2020, 23 Suppl 7:e25616.","journal-title":"J Int AIDS Soc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab297","article-title":"Case report: emergent resistance in a treatment-naive person with human immunodeficiency virus under bictegravir-based therapy","volume":"8","author":"Chamberlain N","year":"2021","unstructured":"Chamberlain N, Mena L, Brock JB. Case report: emergent resistance in a treatment-naive person with human immunodeficiency virus under bictegravir-based therapy. Open Forum Infect Dis. 2021, 8:ofab297. 10.1093\/ofid\/ofab297","journal-title":"Open Forum Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000180095.12276.ac","article-title":"HIV drug resistance acquired through superinfection","volume":"19","author":"Smith DM","year":"2005","unstructured":"Smith DM, Wong JK, Hightower GK, et al.. HIV drug resistance acquired through superinfection. AIDS. 2005, 19:1251-6. 10.1097\/01.aids.0000180095.12276.ac","journal-title":"AIDS"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra025195","article-title":"HIV drug resistance","volume":"350","author":"Clavel F","year":"2004","unstructured":"Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004, 350:1023-35. 10.1056\/NEJMra025195","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(16)30469-8","article-title":"Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study","volume":"17","author":"Gregson J","year":"2017","unstructured":"Gregson J, Kaleebu P, Marconi VC, et al.. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infect Dis. 2017, 17:296-304. 10.1016\/s1473-3099(16)30469-8","journal-title":"Lancet Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458433-treatment-emergent-bictegravir-resistance-in-a-treatment-naive-individual-with-hiv-infection-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:42:03Z","timestamp":1774982523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458433-treatment-emergent-bictegravir-resistance-in-a-treatment-naive-individual-with-hiv-infection-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.106218","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}